VolitionRx. Triage test ready for launch. Triage test can reduce colonoscopies by 25% VolitionRx: Market of 150m in triage tests per year
|
|
- Noel Camron Hodge
- 7 years ago
- Views:
Transcription
1 VolitionRx Triage test ready for launch Commercial update Healthcare equipment & services VolitionRx reported in January 2017 that it had received a CE mark for its Nu.Q triage test for colorectal cancer (CRC). The company is targeting commercialization of the test initially in EU member states that have established fecal immunochemical testing (FIT) programs (of which there are 14 in total), and the CE mark should enable launches in these territories as early as Year end Revenue PBT* EPS* ($) 12/ (8.4) (0.62) 0.0 N/A N/A DPS ($) P/E (x) Yield 12/ (9.7) (0.54) 0.0 N/A N/A 12/16e 0.0 (14.0) (0.61) 0.0 N/A N/A 12/17e 1.6 (16.6) (0.62) 0.0 N/A N/A Note: *PBT and EPS are normalized, excluding amortization of acquired intangibles, exceptional items and share-based payments. 6 January 2017 Price US$5.26 Market cap US$137m Net cash at end Q Shares in issue 26.1m Free float 74% Code VNRX Primary exchange NYSE MKT Secondary exchange N/A Share price performance Triage test can reduce colonoscopies by 25% In October 2016 VolitionRx presented data at the European Society for Medical Oncology detailing the results from a 1,907-person prospective clinical trial of the Nu.Q triage test. The results demonstrated that when combined with a FIT, the protocol could maintain 96.6% of CRC diagnoses compared to current regimens, while reducing unnecessary colonoscopies by 25%. Additional results are to be released in February 2017 at the ENDO 2017 World Congress of GI Endoscopy. VolitionRx: Market of 150m in triage tests per year The company announced initial pricing and market estimates for the triage test on the Q316 conference call. The assay will be priced at 50 per test, and VolitionRx estimates approximately three million people with positive FITs across Europe, which is similar to our estimates of 2.5 million individuals. The company expects individual contracts with central health authorities to translate into 30k to 200k tests per year apiece, depending on the size of the country. Big prospective trial on deck The company announced plans to initiate a prospective trial of 30,000 Danish individuals for the study of the front-line Nu.Q test in collaboration with Hvidovre Hospital. The trial will follow patients for a minimum of two years with an option to extend up to six years, and will cost DKK7.5m per year in fees to the hospital. Valuation: $267m or $10.23 per basic share We have increased our valuation to $267m from $246m, but the per-share valuation has reduced to $10.23 from $10.46 per basic share due to the recent 2.5m share offering. We have increased our peak sales estimates for the triage test to $42m from $30m based on company pricing guidance, and increased our valuation for the program to $17m from $12m. The remainder of the increase is due to advancing our NPVs to Q316, and the October 2016 offering ($11.7m net). We expect the company to need $45m in cash before becoming cash flow positive in % 1m 3m 12m Abs Rel (local) week high/low US$5.6 US$3.1 Business description VolitionRx is a diagnostics company focused on developing blood-based cancer diagnostics using its proprietary Nu.Q technology. Its lead program is in colorectal cancer, which may enter the European market in Next events Additional triage trial results at ENDO congress Additional CRC data FDA feedback on 510(k) pathway Analysts February 2017 H117 H117 Maxim Jacobs Nathaniel Calloway healthcare@edisongroup.com Edison profile page VolitionRx is a research client of Edison Investment Research Limited
2 CE mark received for triage test in Europe VolitionRx announced in January 2017 that it had received a CE mark for the Nu.Q triage colorectal cancer (CRC) test and it is now authorized for sale in Europe. The triage test will be the company s first product available for purchase and the first sales are expected in H117. The test uses the Nu.Q nucleosome testing platform and two assays that were previously used in the first-line Nu.Q CRC test currently in development. The triage test is designed to decrease the number of unnecessary colonoscopies by providing an additional layer of screening on top of the standard fecal immunochemical test (FIT). FIT screening is the standard first-line detection method across Europe, and approximately 2.6% of patients receive a false positive for the test in trials, but the rate of positive tests is much higher in retrospective studies: up to 7%. 1,2 Based on the underlying rate of CRC, the company estimates that 95% of all positive FITs are false positives, due to the low underlying prevalence of CRC. There is therefore a substantial burden placed on healthcare systems due to unnecessary colonoscopies. This is particularly the case in systems that have government-sponsored FIT screening, which is present in 14 of the 28 EU member states. The company released results at the European Society for Medical Oncology (ESMO) from a 1,907-person prospective study demonstrating that the triage test, when combined with a FIT, can reduce the rate of unnecessary colonoscopies by 25%, while correctly identifying 96.6% of CRC cases (compared to current colonoscopy rates). Additionally, the two tests combined are better at positively identifying patients with CRC: 29% more cases of CRC were caught using the triage test and FIT compared to FIT alone. This corresponds to a sensitivity of 88% and specificity of 98.1%, when extrapolated using historical FIT data (Exhibit 1). The full results of the triage clinical trial will be presented at the ENDO 2017 World Congress of GI Endoscopy in February. Exhibit 1: CRC screening technology comparison Test Sensitivity False negative Specificity False positive rate Cost per test rate Colonoscopy $1,000-3,000 FOBT $5 FIT $23 Cologuard (Exact Sciences) $649 Nu.Q triage + FIT* Source: FDA, World Gastroenterology Organisation, Exact Sciences, VolitionRx. Note: *These data extrapolated from VolitionRx reported improvements and historical FIT measurements. On the Q316 conference call, VolitionRx provided preliminary pricing and market estimates. VolitionRx stated that it is aiming to price the test in the 50 range, which is higher than our earlier estimates of 20 per test, and the company provided a range of gross s for the test: north of 70% or 80%. The test will be commercialized by targeting central health authorities across the EU, beginning with the states that have established FIT testing protocols. The company estimated a potential market of 3m tests per year, which is similar to our earlier estimates of 2.5m across EU member states. The company stated that individual markets in the initial set of targeted territories correspond to chunks of between 30k and 200k tests, depending on the size of the country. 1 2 Quintero E, et al. (2012) Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. New Eng. J. Med. 366, Imperiale TF, et al. (2014) Multitarget Stool DNA Testing for Colorectal-Cancer Screening. New Eng. J. Med. 370, VolitionRx 6 January
3 Biggest CRC trial yet In other developments, VolitionRx announced that it will be initiating a 30,000-person prospective screening study in Denmark with its long-time collaborator Hvidovre Hospital of the front-line Nu.Q CRC test. The study is the company s largest to date and its prospective nature should provide significant evidence of the test s utility for widespread screening. The previous prospective CRC study enrolled only 121 patients, but showed 91% sensitivity and 90% specificity. The patients on the study will be selected from the Danish FIT screening program on the basis of a negative FIT, and will receive a Nu.Q test on enrolment and each subsequent year. The program has an initial duration of two years with the option to continue for up to six years. We expect at least one year for enrollment, corresponding to a maximum seven-year clinical program. The company will pay the hospital DKK7.5m per year ($1.1m) for the study. These expenses are within our estimates for the development costs for the front-line test. Depending on results, such a study may support marketing efforts in Europe, but marketing approval and payer adoption in the US may require additional studies, although in the near term the company may avoid some clinical trials by pursuing a 510(k) approval, albeit with a more restrictive label. Feedback from the FDA on the US approval pathway, starting with guidance on a 510(k) application, is expected in H117. We also expect results from two other studies being performed at Hvidovre Hospital in H117: a 4,800-person study of biomarkers to differentiate CRC from other bowel diseases, and a 14,000-person study in patients with a positive FIT test. Valuation We have increased our valuation to $267m from $246m, although this represents a reduction in the per-share valuation to $10.23 from $10.46 per basic share because of the October 2016 offering of 2.5m shares for a net $11.7m. Approximately $6m of this increase is due to the integration of the pricing and s reported by the company for the Nu.Q CRC triage test. The price increase has been made at the cost of a slower rate of adoption, although we have increased our peak sales estimates to $42m (from $30m). The gross estimates from the company have reduced our expected peak estimates from 54% to 50%. The remainder of the increase in valuation is due to advancing our NPVs to Q316, offset by a lower cash balance. We expect to update our valuation following feedback from the FDA on the 510(k) pathway, as well as reports of the Nu.Q triage launch. VolitionRx 6 January
4 Exhibit 2: VolitionRx valuation Product Main indication Status Prob. of commercial success Launch year Peak sales Patent protection Economics Nu.Q Colorectal Development 30% 2017 $ % peak $175 Colorectal triage Pre-commercialization 30% 2016 $ % peak $17 Lung Development 30% 2018 $ % peak $41 Pancreatic Development 30% 2018 $ % peak $10 Total $243 Cash and cash equivalents (Q316 + offering) $24.2 Total firm value $267 Total basic shares (m) 26.1 Value per basic share ($) $10.23 Warrants and options (9/2016, m) 2.1 Weighted average exercise price ($) $2.36 Cash on exercise $5.0 Total firm value $272 Non-warrant options (6/2016, m) 2.5 Total number of shares (m) 30.7 Diluted value per share ($) $8.86 Source: VolitionRx reports, Edison Investment Research rnpv Financials The company ended Q316 with $12.5m in cash following an operating loss for the quarter of $3.5m. This loss is an increase over previous quarters ($3.0m in Q216 and $2.5m in Q116), reflecting an increase in R&D spending associated with advancement of the Nu.Q CRC development program ($2.0m for the quarter). However, the increase in spending during the quarter was lower than expected, and we have reduced 2016 full year operational loss estimates to $14.0m from $15.1m, although there is little carry-over into future years. The company has subsequently completed an offering (2.5m shares at $5.00 for $11.7m in net proceeds). This raise has reduced our expected funding requirement to $45m ($15m in 2017, $15m in 2018, and $15m in 2019) from previous estimates of $60m. We expect that the company will be cash flow positive in VolitionRx 6 January
5 Exhibit 3: Financial summary $000s e 2017e Year end 31 December IFRS IFRS IFRS IFRS IFRS IFRS PROFIT & LOSS Revenue ,622 Cost of Sales (229) Gross Profit ,393 Research & Development (2,843) (2,504) (4,044) (6,102) (8,002) (9,902) Sales, General & Administrative (1,295) (2,072) (1,908) (3,904) (6,051) (8,171) EBITDA (4,083) (4,576) (5,937) (10,006) (14,027) (16,679) Operating Profit (before GW and except.) (4,083) (4,576) (5,937) (10,006) (14,027) (16,679) Intangible Amortization Other Exceptionals Operating Profit (4,083) (4,576) (5,937) (10,006) (14,027) (16,679) Net Interest Other (39) 840 (2,320) 471 (34) 0 Profit Before Tax (norm) (4,083) (4,576) (8,358) (9,666) (14,027) (16,583) Profit Before Tax (FRS 3) (4,122) (3,736) (8,258) (9,535) (14,060) (16,583) Tax 0 0 (0) Deferred tax 0 0 (0) (0) (0) (0) Profit After Tax (norm) (4,083) (4,576) (8,358) (9,661) (14,027) (16,583) Profit After Tax (FRS 3) (4,122) (3,736) (8,258) (9,530) (14,060) (16,583) Average Number of Shares Outstanding (m) EPS - normalised (c) (43.62) (42.24) (62.08) (54.49) (60.78) (62.31) EPS - FRS 3 ($) (0.44) (0.34) (0.61) (0.54) (0.61) (0.62) Dividend per share ($) BALANCE SHEET Fixed Assets 1,522 1,065 1,097 1,489 1,423 1,269 Intangible Assets 1,430 1, Tangible Assets Other 0 0 (0) (0) (0) (0) Current Assets ,192 6,070 19,502 19,591 Stocks Debtors Cash ,139 5,916 19,349 19,137 Other Current Liabilities (695) (957) (2,713) (1,120) (1,907) (1,740) Creditors (695) (957) (2,713) (1,120) (1,907) (1,740) Short term borrowings Long Term Liabilities (635) (433) (352) (548) (460) (15,460) Long term borrowings (15,000) Other long term liabilities (635) (433) (352) (548) (460) (460) Net Assets ,891 18,559 3,660 CASH FLOW Operating Cash Flow (2,315) (3,084) (4,141) (8,766) (11,578) (15,373) Net Interest Tax Capex (91) (1) (303) (352) (89) (30) Acquisitions/disposals Financing 2,576 2,828 5,627 12,498 25,206 0 Dividends Other (62) 0 Net Cash Flow 171 (257) 1,183 3,379 13,477 (15,403) Opening net debt/(cash) (348) (376) (889) (2,139) (5,916) (19,349) HP finance leases initiated Exchange rate movements (40) 4 (44) Other (103) (77) 191 Closing net debt/(cash) (376) (889) (2,139) (5,916) (19,349) (4,137) Source: VolitionRx reports, Edison Investment Research VolitionRx 6 January
6 Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt and Sydney. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number ) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [ ] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [ ]. DISCLAIMER Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by VolitionRx and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are wholesale clients for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a personalised service and, to the extent that it contains any financial advice, is intended only as a class service provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ( FTSE ) FTSE FTSE is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE s express written consent. Frankfurt +49 (0) VolitionRx Schumannstrasse 34b 6 January High Holborn 245 Park Avenue, 39th Floor Level 25, Aurora Place Frankfurt Germany London +44 (0) London, WC1V 7EE United Kingdom New York , New York US Sydney +61 (0) Phillip St, Sydney NSW 2000, Australia
Evolva. Stevia delayed. Stevia delay. Saffron to be partnered, resveratrol has bottlenecks. Valuation: Fair value of CHF1.14/share.
Evolva Stevia delayed FY results Food & beverages The key headline that the launch of the stevia EverSweet product has been delayed is disappointing, but the investment case still stands. A short-term
More informationAlternative asset management
DeA Capital Transformation continues Q215 results Investment companies DeA Capital s NAV per share at 30 June 2015 was 2.18, which compares to 2.15 at 31 March 2015 (after adjusting for the capital distribution
More informationExpert System. Strong organic growth with acquisition upside. Growth in annual licensing key to shareholder return
Expert System Strong organic growth with acquisition upside Acquisition and order update Software & comp services Expert Systems has announced encouraging order growth, with US orders up 82% and annual
More informationDanakali. Maiden ore reserve underpins valuation upside. Maiden 1.1Bt ore reserve at Collulli
Danakali Maiden ore reserve underpins valuation upside Company update Metals & mining Since the release of its PFS in February 2015, Danakali (DNK) has continued on its path towards production with the
More informationMonitise. Shifting to a subscription model. Shifting to a subscription-based revenue model. Funding the change
Monitise Shifting to a subscription model Fund-raising Software & comp services Monitise is shifting to a subscription-based revenue model to accelerate customer adoption and drive higher long-term recurring
More informationMonitise. Positive momentum. Trading update: FY13 on track. Recent contract wins highlight service expansion. M-commerce opportunity for banks
Monitise Positive momentum Trading update and contract wins Software & comp services Monitise s trading update confirms that it will meet FY13 guidance, with revenue growth of at least 94% y-o-y and gross
More informationWANdisco Acquisition. Acquisition accelerates big data. Technology. A start up, founded by key Hadoop contributors
WANdisco Acquisition Acquisition accelerates big data Technology WANdisco s acquisition of AltoStor for $5.1m in cash and shares marks a significant advance in its drive to establish a position at the
More informationInvestment Case Study - Tigenix
TiGenix Refocused and funded FY14 results Pharma & biotech Tigenix's FY14 results show a company now completely refocused on the proprietary allogeneic easc technology platform and pipeline where the commercial
More informationNAHL Group. Better than expected FY14 EPS and dividend. Strong FY14 results. Key growth strategy element: First acquisition made
NAHL Group Better than expected FY14 EPS and dividend Preliminary results Financial services NAHL s maiden full year results show strong growth of 29.3% in underlying operating profit on continuing operations
More informationIS Private Equity. Another year of record profits. Realised gains drive record profits. Exits appear well timed. Valuation: NAV not marked to market
IS Private Equity Another year of record profits FY results Investment companies 2013 reported consolidated net profits at Is Private Equity (ISGSY) were a record TRY68.7m (2012: TRY50.3m). A realised
More informationAFH Financial Group. Deploying the capital as promised. H115 key trends. Outlook. Valuation: Material upside. H115 interim results
AFH Financial Group Deploying the capital as promised H115 interim results Financial services AFH has both organic and inorganic strands to its strategy. H115 on H114 delivered 13% revenue growth of which
More informationSlater & Gordon. FY14 ahead of forecasts. FY14 key issues. Outlook. Valuation: Around fair value. FY14 results
Slater & Gordon FY14 ahead of forecasts FY14 results Financial services SGH s FY14 results were ahead of expectations driven by a beat in UK revenue. We believe this, and two new Australian acquisitions
More informationSlater & Gordon. Deal generates material earnings enhancement. Strategic logic. How can such an uplift to EPS be achieved?
Slater & Gordon Deal generates material earnings enhancement Acquisition of Quindell PSD Financial services Slater & Gordon (SGH) has announced the terms of its acquisition of Quindell s Professional Services
More informationFastnet Oil & Gas. Game on at Foum Assaka. Continuing to deliver on schedule in Morocco. FA-1 breaking new ground
Fastnet Oil & Gas Game on at Foum Assaka Drilling underway Oil & gas Having secured the most valuable farm-out terms of all the junior explorers offshore Morocco, Fastnet is now drilling its first well,
More informationMonitise Share placing and acquisitions
Monitise Share placing and acquisitions More mobile money In order to further its m-commerce ambitions, Monitise has raised 100m from its largest placing to date, and has also made two all-share acquisitions
More informationBorussia Dortmund. Still much to play for. Après Champions League, pas de déluge! Current-year profit resilience. Valuation: Attractive
Borussia Dortmund Still much to play for Revised forecasts Travel & leisure Despite a stalled Bundesliga recovery and coach Klopp s end-of-season departure, Borussia Dortmund is well-placed to end FY15
More informationDetecting Cancer in Blood. Company presentation
Detecting Cancer in Blood Company presentation Safe harbor statement Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation, statements
More informationNOMAD FOODS LIMITED ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2016
NOMAD FOODS LIMITED ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2016 FELTHAM, United Kingdom, May 25, 2016 /PRNewswire/ Nomad Foods Limited ( Nomad or the Company ) (NYSE: NOMD), today
More informationSportingbet Plc. Sportingbet Plc, a leading online sports betting and gaming group, announces its results for the half year ended 31 January 2012.
Unaudited results for the half year ended 31 January 2012 Sportingbet Plc, a leading online sports betting and gaming group, announces its results for the half year ended 31 January 2012. Group Financial
More informationBDI BioEnergy Intern. 20.0 Neutral. Activity level in Q3 might not support FY estimates
8/11/1 8/1/11 8/3/11 8/5/11 8/7/11 8/9/11 8/11/11 8/1/12 8/3/12 8/5/12 8/7/12 8/9/12 MATELAN Research Preview Note Price as of 9/11/12: 8.69 12 November 212 Company / Sector Fair Value Recommendation BDI
More informationZebra Technologies Announces Record Sales for Second Quarter of 2006
FOR IMMEDIATE RELEASE Zebra Technologies Announces Record Sales for Second Quarter of 2006 Vernon Hills, IL, July 26, 2006 Zebra Technologies Corporation (NASDAQ: ZBRA) today announced that net income
More informationAlkane Resources. Update. Investment summary: Dubbo DFS. Market Cap. Continuing price increases DZP highly cash generative
Update 28 September 2011 Alkane Resources Price Market Cap A$1.06 A$285m Year End Revenue (A$m) PBT* (A$m) EPS* (c) DPS (c) P/E (x) Yield (%) Share price graph 12/09 **4.7 2.4 1.0 0.0 106.0 N/A 12/10 **10.1
More informationDisclaimer. This document has been prepared by Tele Columbus AG (the "Company") solely for informational purposes.
Disclaimer This document has been prepared by Tele Columbus AG (the "Company") solely for informational purposes. This presentation may contain forward-looking statements. These statements are based on
More informationEQUITY DERIVATIVES NZX DERIVATIVES MARKET. www.nzx.com
EQUITY DERIVATIVES NZX DERIVATIVES MARKET www.nzx.com WHAT ARE EQUITY DERIVATIVES? Equity derivatives are among the most traded financial instruments globally with volume traded of 11.77 billion in 2013.
More informationHow To Value A Rarex Bionics Stock
Rex Bionics The Robotic physiotherapist Initiation of coverage Tech hardware & equipment Rex Bionics is a pioneer in the field of medical exoskeletons. It is focused on rehabilitating and improvement in
More informationKing Reports First Quarter 2014 Results
King Reports First Quarter 2014 Results Generates record quarterly mobile gross bookings of $480 million in Q1-14 Adjusted EBITDA more than triples year over year to $249 million in Q1-14 Extends reach
More informationDATRON AG. Investor day supports our positive view. Buy (Buy) 12.50 EUR (12.50 EUR ) BANKHAUS LAMPE // 1 17/09/2015
BANKHAUS LAMPE // 1 DATRON AG Investor day supports our positive view 17/09/2015 Buy (Buy) 12.50 EUR (12.50 EUR ) Close 15/09/2015 9.75 EUR Bloomberg: DAR GY WKN: A0V9LA Sector Engineering Share price
More informationInspired Energy. Realising the growth potential. Strong growth record. Order book provides platform for growth. Valuation: Pricing growth
Inspired Energy Realising the growth potential Initiation of coverage Industrial support services Inspired Energy is well placed to take advantage of the growth opportunities afforded by the fast-growing
More informationHow To Profit From A Profit From The Year
Results for the 12 months ended 30 June 2014 28 th August 2014 Peter George, CEO Geoff Stephenson, CFO INVESTOR PRESENTATION 2 Contents FY14 Highlights Reconciliation of EBITDA Transformation Financial
More informationK3 BUSINESS TECHNOLOGY GROUP POSITIVE OUTLOOK REITERATED. In-line numbers and healthy prospects across the divisions SOFTWARE & COMPUTER SERVICES
K3 BUSINESS TECHNOLOGY GROUP SOFTWARE & COMPUTER SERVICES KBT.L 129.5p Market Cap: 40.7m SHARE PRICE PERFORMANCE 190 170 150 130 110 90 70 50 Sep-12 Nov-12 Jan-13 Mar-13 May-13 Jul-13 12m high/low 176p/93p
More informationEQUITY RAISING ANNOUNCEMENT
EQUITY RAISING ANNOUNCEMENT MARKET RELEASE 21 NOVEMBER 2012 KEY POINTS Entitlement Offer to Raise up to A$80 million o 3 for 10 accelerated non renounceable entitlement offer to raise up to A$80 million
More informationClime Capital Limited (CAM)
Clime Capital Limited (CAM) Listed Managed Investments September 2012 Quarterly Review WHO IS IIR? Independent Investment Research Pty Ltd, IIR is an independent investment research house in Australia.
More information2015 annual results. 16 th March 2016
2015 annual results 16 th March 2016 Legal disclaimer Certain statements in this document are forward-looking statements. These forward-looking statements speak only as at the date of this document. These
More informationSmart Metering Systems plc. Interim Results For the half year ended 30 June 2015
Smart Metering Systems plc Interim Results For the half year ended 2015 Introduction and agenda Business review Alan Foy, CEO SMS story Financial Operational Financial review Glen Murray, CFO Highlights
More informationEarnings Conference Call Q1 2016 Update Wednesday, May 25 th 2016
Earnings Conference Call Q1 2016 Update Wednesday, May 25 th 2016 These materials may not be used or relied upon for any purpose other than as specifically contemplated by a written agreement with Credit
More informationBUY Target: 215p. Strategic impact: cross-selling. Financial impact: good value
UK Daily Letter 1 K3 Business Technology Group KBT : AIM : 144p BUY Target: 215p Bob Liao, CFA 44.20.7050.6654 bliao@canaccordgenuity.com COMPANY STATISTICS: 52-week Range: 0.82-1.50 Avg. Daily Vol. (000s):
More informationNIGHTINGALE REPORTS FISCAL 2014 RESULTS
NIGHTINGALE REPORTS FISCAL 2014 RESULTS Markham, ON, July 31, 2014 Nightingale Informatix Corporation ( Nightingale or the Company ) (TSX-V: NGH), an application service provider (ASP) of electronic health
More information5 November 2014 Pharming Group NV. FIRST BERLIN Equity Research. 9M 2014 Results & US Product Launch
FIRST ERLIN Equity Research Netherlands / iotechnology Primary exchange: Euronext Amsterdam / Secondary exchange: Frankfurt 9M 2014 Results & US Product Launch 5 P ha RATING UY PRICE TARGET 1.50 loomberg:
More informationYear ended 31 Dec 2009
PACE PLC CHANGE OF FUNCTIONAL AND PRESENTATIONAL CURRENCY AND COMPARATIVES RE-PRESENTED IN US DOLLARS Introduction Pace announced at the time of its preliminary results announcement that the Board had
More informationYear-end Dec 2013A 2014E 2015E 2016E Key data. # Priced at market close, 29/09/14
This research is intended for UK institutional investors only and market professionals. It is not intended for retail customers and any retail customer should seek professional, independent advice before
More informationeuromicron AG Corrections to financial statements Hold 14.00 EUR
euromicron AG Corrections to financial statements 24/03/2015 Hold 14.00 EUR Close (23/03/2015) Bloomberg: EUCA Sector Share price performance 14.15 EUR WKN: A1K030 Technology 52 week high 14.18 52 week
More informationInternational Financial Reporting Standards (IFRS)
FACT SHEET June 2010 IFRS 3 Business Combinations (This fact sheet is based on the standard as at 1 January 2010.) Important note: This fact sheet is based on the requirements of the International Financial
More informationBackground information. Changes in the shareholder structure and balance sheet. Contract with Google prolonged for two years
A cc or # $T ypcap$ 1628 1 0 4 2 Page 1/5 Equity flash Newsflow Telecommunication HOLD (HOLD) Target EUR 4.00 (EUR 4.00) Price (last closing price) : EUR 2.84 Upside : 40 % Est. change 2015e 2016e EPS
More informationQ2 2015 Financial Results and Key Metrics
Q2 2015 Financial Results and Key Metrics August 13, 2015 Non-GAAP financial measures King Digital Entertainment plc (the Company ) uses International Financial Reporting Standards ( IFRS ). In addition
More informationTORSTAR CORPORATION REPORTS SECOND QUARTER RESULTS
PRESS RELEASE TORSTAR CORPORATION REPORTS SECOND QUARTER RESULTS TORONTO, ONTARIO (Marketwired July 30, 2014) Torstar Corporation (TSX:TS.B) today reported financial results for the second quarter ended
More informationInternational Financial Reporting Standards (IFRS)
FACT SHEET September 2011 IAS 7 Statement of Cash Flows (This fact sheet is based on the standard as at 1 January 2010.) Important note: This fact sheet is based on the requirements of the International
More informationTrxade Group, Inc. (TCQB: TRXD): Record Revenues in Q3
Siddharth Rajeev, B.Tech, MBA, CFA Analyst November 5, 2015 Trxade Group, Inc. (TCQB: TRXD): Record Revenues in Q3 Sector/Industry: E-commerce Market Data (as of November 5, 2015) Current Price $1.15 Fair
More informationMonster Worldwide Reports Third Quarter 2015 Results
Monster Worldwide Reports Third Quarter 2015 Results Third Quarter Financial Highlights: o Company Exceeds Expectations on All Profitability Metrics For the 5th Consecutive Quarter Adjusted EBITDA Including
More informationFLOW TRADERS REPORTS STRONG RESULTS IN FIRST HALF YEAR 2015 AND INTERIM DIVIDEND OF 0.50 PER SHARE.
For immediate release FLOW TRADERS REPORTS STRONG RESULTS IN FIRST HALF YEAR 2015 AND INTERIM DIVIDEND OF 0.50 PER SHARE. AMSTERDAM, the Netherlands 19 August 2015. Flow Traders N.V. ( the Company or Flow
More informationDeutsche Wohnen AG.» Full Year Results 2009. Conference Call, 26 March 2010
Deutsche Wohnen AG» Full Year Results 2009 Conference Call, 26 March 2010 1 » Agenda 1. Results of the financial year 2009 2. Financial highlights 2009 3. Strategic objectives 4. Forecast 2 » 1 Results
More informationTD is currently among an exclusive group of 77 stocks awarded our highest average score of 10. SAMPLE. Peers BMO 9 RY 9 BNS 9 CM 8
Updated April 16, 2012 TORONTO-DOMINION BANK (THE) (-T) Banking & Investment Svcs. / Banking Services / Banks Description The Average Score combines the quantitative analysis of five widely-used investment
More informationAnnual Financial Results Presentation for year ended 30 June 2014 2 October 2014
Annual Financial Results Presentation for year ended 30 June 2014 2 October 2014 Disclaimer The information contained in this presentation ( Presentation ) has been prepared by Firestone Diamonds plc (the
More informationSummary of Consolidated Financial Results for the Six Months Ended September 30, 2013
November 6, 2013 Summary of Consolidated Financial Results for the Six Months Ended Name of Company Listed: Stock Exchange Listings: Nippon Paper Industries Co., Ltd. Tokyo Code Number: 3863 URL: Representative:
More informationTHERATECHNOLOGIES INC.
Interim Consolidated Financial Statements of (In thousands of Canadian dollars) THERATECHNOLOGIES INC. Table of Contents Page Interim Consolidated Financial Positions 1 Interim Consolidated Statements
More informationHoist Finance announces its intention to launch an initial public offering and listing on Nasdaq Stockholm
Press release Stockholm 26 February 2015 Hoist Finance announces its intention to launch an initial public offering and listing on Nasdaq Stockholm Hoist Finance AB (publ) ( Hoist Finance or the Company
More informationUTi Worldwide Inc. FISCAL 2002 SECOND QUARTER RESULTS WITH COMMENTARY. September 14, 2001 - 1 -
UTi Worldwide Inc. FISCAL 2002 SECOND QUARTER RESULTS WITH COMMENTARY September 14, 2001 UTi is pleased to present herein its results for the three and six months ended 2001 along with management s commentary
More informationThird quarter results as of December 31, 2014. Investor presentation
Third quarter results as of December 31, 2014 Investor presentation February, 26 th 2015 Disclaimer Certain statements included or incorporated by reference within this presentation may constitute forwardlooking
More informationNEUTRAL. Weak FY14, but positive outlook thereafter. June 5 th, 2015
EQUITY RESEARCH FY14 Update June 5 th, 2015 Weak FY14, but positive outlook thereafter NEUTRAL Current Share Price ( ): 3.4 Target Price ( ): 3.8 Enertronica 1Y Performance 120 Weak FY2014 figures, due
More informationNEWS RELEASE QUESTOR TECHNOLOGY INC. ANNOUNCES FIRST QUARTER 2014 FINANCIAL RESULTS
NEWS RELEASE QUESTOR TECHNOLOGY INC. ANNOUNCES FIRST QUARTER 2014 FINANCIAL RESULTS Calgary, Alberta (May 30, 2014) Questor Technology Inc. ( Questor or the Company ) (TSX-V: QST) announced today its financial
More informationDeutsche Wohnen AG.» German Jour Fixe 1-1 Conference Merrill Lynch. London, 27 April 2010
Deutsche Wohnen AG» German Jour Fixe 1-1 Conference Merrill Lynch London, 27 April 2010 1 » Agenda 1. Deutsche Wohnen at a glance 2. Results of the financial year 2009 3. Financial highlights 2009 4. Strategic
More informationComprehensive review of the IFRS for SMEs Summary of user outreach (October 2014)
(October 2014) Objective of this paper 1. This paper gives an overview of the user outreach performed by the staff during the initial comprehensive review of the IFRS for SMEs and summarises the feedback
More informationDATA GROUP LTD. ANNOUNCES FIRST QUARTER RESULTS FOR 2014
For Immediate Release DATA GROUP LTD. ANNOUNCES FIRST QUARTER RESULTS FOR 2014 HIGHLIGHTS Q1 2014 First quarter 2014 ( Q1 ) Revenues of 77.9 million, Q1 Gross Profit of 18.8 million and Q1 Net Income of
More informationCONSOLIDATED STATEMENT OF INCOME
CONSOLIDATED STATEMENT OF INCOME 4 th quarter (a) 3 rd quarter 4 th quarter 2009 Sales 40,157 40,180 36,228 Excise taxes (4,397) (4,952) (4,933) Revenues from sales 35,760 35,228 31,295 Purchases, net
More informationMedia Contact: Mike Conway Director, Corporate Communications Sherwin-Williams Direct: 216.515.4393 Pager: 216.422.3751 mike.conway@sherwin.
The Sherwin-Williams Company Reports First Quarter 2012 Financial Results Consolidated net sales increased 15.1% to a record $2.14 billion Diluted net income per common share increased 50.8% to a record
More informationB U I L D I N G N O R T H A M E R I C A N F I N T E C H L E A D E R S H I P. BMO 2013 Technology and Digital Media Conference
B U I L D I N G N O R T H A M E R I C A N F I N T E C H L E A D E R S H I P BMO 2013 Technology and Digital Media Conference Forward-Looking Statements This presentation contains certain statements that
More informationEVERYDAY HEALTH, INC.
EVERYDAY HEALTH, INC. FORM 8-K (Current report filing) Filed 05/11/15 for the Period Ending 05/11/15 Address 345 HUDSON STREET 16TH FLOOR NEW YORK, NY 10014 Telephone 718-797-0722 CIK 0001358483 Symbol
More informationFull year and fourth quarter 2014 results 1
Full year and fourth quarter results 1 Luxembourg, February 12, 2015 Highlights Health and Safety frequency rate 2 of 1.1x in compared to 1.3x in 2013. Shipments of 1,813 thousand tonnes in full year,
More informationKabel Deutschland shows continued growth with Internet & Phone
INVESTOR RELATIONS RELEASE Kabel Deutschland shows continued growth with Internet & Phone Unterfoehring, February 12, 2016 Kabel Deutschland Holding AG ( Kabel Deutschland, KDH or the Company ), Germany
More informationTHINKSMART REVENUE UP 30% - ON TRACK TO ACHIEVE FULL YEAR PROSPECTUS FORECASTS
ANNOUNCEMENT 29 th August, 2007 THINKSMART REVENUE UP 30% - ON TRACK TO ACHIEVE FULL YEAR PROSPECTUS FORECASTS ThinkSmart Limited (ASX:TSM) today reported a half year profit before tax for the six months
More informationBIOMARK DIAGNOSTICS INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS. June 30, 2015. (Stated in Canadian Dollars)
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited Prepared by Management) NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Under National Instrument 51-102,
More informationFull Year Report 2005. 26 January 2006
Full Year Report 2005 26 January 2006 Important Notice This Presentation has been produced by TradeDoubler AB (the Company ) and is furnished to you solely for your information. This document contains
More informationico Therapeutics Inc. Condensed Interim Financial Statements (Unaudited) September 30, 2012 and 2011 (in Canadian dollars)
Condensed Interim Financial Statements (Unaudited) September 30, 2012 and 2011 Balance Sheet (Unaudited) Assets Note September 30, 2012 December 31, 2011 Current assets Cash and cash equivalents 1,478,167
More informationInvesco s guide to your tax statement
Invesco s guide to your tax statement June 2016 This guide has been prepared by Invesco to assist you in completing your income tax return for the year ended 30 June 2016. This guide relates only to your
More informationINVESTMENT CASE FULLY INTACT
Leifheit AG Q2 results due out on 12/08/2015 07/08/2015 INVESTMENT CASE FULLY INTACT Buy 60.00 EUR Close (06/08/2015) 47.68 EUR Bloomberg: LEI WKN: 646450 Sector Share price performance Consumer 52 week
More informationLaunch Announcement for Warrants to be issued by
This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the Warrants described below. Hong Kong Exchanges and Clearing
More informationCooks Global Foods. Growing the global footprint. Building a global brand. Recapitalisation plan
Cooks Global Foods Growing the global footprint Company outlook Food & beverages Cooks Global Foods (CGF) is ready to take the Esquires Coffee House franchise to the next phase, with a new plan to fund
More informationConsolidated Financial Results for the nine months of Fiscal Year 2010
Consolidated Financial Results for the nine months of Fiscal Year 2010 (Fiscal Year 2010: Year ending March 31, 2010) Noritake Co., Limited Company Name Stock Exchange Listings Tokyo, Nagoya Code Number
More informationFor Required Non-U.S. Analyst and Conflicts Disclosures, please see page 8. Exhibit 1: Average 3mo/6mo/1yr returns following a federal election
RBC Dominion Securities Inc. Javed Mirza, CFA, CMT (Analyst) (416) 842-8744 javed.mirza@rbccm.com October 19, 2015 Elections and Equity Markets A Canadian Perspective Summary The latest advance polls tracking
More informationClosed-end fund update
a b Closed-end fund update Senior loan funds: Too early to Buy UBS Wealth Management Research / 29 May 2008 Lead Analyst Sangeeta Marfatia Highlights We provide an update on the senior loan funds in this
More informationChange (%) Six months ended June 30, 2013 Six months ended June 30, 2012. Operating income ( million) Change (%) 24.6 133.1.
Consolidated Financial Statements for the First Half of 2013 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in
More informationGEFRAN. 1Q16 results in line. Buy (maintained) Company report. 13 May 2016. Electrical equipment
GEFRAN Company report Electrical equipment Data Shares Outstanding (m): 14 Market Cap. (EURm): 25 Enterprise Value (EURm): 55 Free Float (%): 33.2% Av. Daily Trad. Vol. (m): 0.01 Main Shareholder: Reuters/Bloomberg:
More informationDr. Reddy s Q3 and 9M FY16 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT
More informationOppenheimer Holdings Inc. Second Quarter 2012 Earnings and Dividend Announcement
Oppenheimer Holdings Inc. NYSE OPY July 27, 2012 New York, NY Second Quarter 2012 Earnings and Dividend Announcement Expressed in thousands of dollars, except per share amounts (unaudited) Three Months
More informationMGC Diagnostics Corporation Reports Fiscal Year 2015 Financial Results
MGC Diagnostics Corporation 350 Oak Grove Parkway Saint Paul, MN 55127 Telephone: (651) 484-4874 Facsimile: (651) 484-4826 FOR IMMEDIATE RELEASE MGC Diagnostics Corporation Reports Fiscal Year 2015 Financial
More informationNet sales Operating income Ordinary income
Consolidated Financial Statements Summary May 10, 2016 (For the year ended March 31, 2016) English translation from the original Japanese-language document (All financial information has been prepared
More informationConsolidated Statement of Profit or Loss (in million Euro)
Consolidated Statement of Profit or Loss (in million Euro) Q2 2012 Q2 2013 % H1 2012 H1 2013 % Restated * change Restated * change Revenue 779 732-6.0% 1,513 1,437-5.0% Cost of sales (553) (521) -5.8%
More informationEmpresaria (EMR.L) Empressive finish to the year
26 th January 2015 56 54 52 50 48 46 EMR EMPRESARIA ORD 5P Empresaria (EMR.L) Empressive finish to the year 44 42 40 38 Q1-2014 Q2-2014 Q3-2014 Q4-2014 Price: 43.0p Sourc e: Fides s a 12m High 56.0p 12
More informationCORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER 2016
CORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER 2016 Financial results in line with plan Cash and cash equivalents of EUR 25.5 million; cash reach until the end
More informationCapcon Holdings plc. Interim Report 2011. Unaudited interim results for the six months ended 31 March 2011
Capcon Holdings plc Interim Report 2011 Unaudited interim results for the six months ended 31 March 2011 Capcon Holdings plc ("Capcon" or the "Group"), the AIM listed investigations and risk management
More informationASX Announcement. Presentation by David Griffith to Morgans Conference
ASX Announcement 21 October 2015 Presentation by David Griffith to Morgans Conference Attached is a presentation to be given later today by IPH s Managing Director, David Griffith to the Morgans Annual
More informationNEWS CORPORATION REPORTS THIRD QUARTER RESULTS FOR FISCAL 2016
NEWS CORPORATION REPORTS THIRD QUARTER RESULTS FOR FISCAL 2016 FISCAL 2016 THIRD QUARTER KEY FINANCIAL HIGHLIGHTS Revenues of $1.9 billion compared to $2.0 billion in the prior year Total Segment EBITDA
More informationAltus Group Reports First Quarter Financial Results for 2015
Street Smart. World Wise. Altus Group Reports First Quarter Financial Results for 2015 Altus Group Delivers 14% Revenue Growth, Including 43% Increase in Recurring Revenues from GAIM Businesses TORONTO,
More informationHi-Media: Recovery in advertising business and significant increase in profitability after the downturn observed in H2 2012
Hi-Media: Recovery in advertising business and significant increase in profitability after the downturn observed in H2 2012 Return to growth in advertising thanks to the success of new advertising solutions
More informationFinancials and valuation Year end: 31 December Price Performance. Source: Company accounts/investec Securities estimates
Company Research Buy 299p 350p Devro (Buy - T P: 350p) 05 August 2015 Devro (DVO.L) United Kingdom Food Producers Strong demand and projects on schedule A good 1H result for Devro which reflects a better
More informationThe Merchant Securities FTSE 100. Hindsight II Note PRIVATE CLIENT ADVISORY
The Merchant Securities FTSE 100 Hindsight II Note Our first FTSE-100 Hindsight Note is now fully subscribed; however, as a result of exceptional investor demand we are launching the FTSE- 100 Hindsight
More informationSep 30 2012. Sep 30 2011. Change %
Pethealth Inc. announces quarterly revenue of $9,303,000 and profit of $892,000 and its full results for the quarter and nine months ended September 30,. OAKVILLE, ON, November 7,. (TSX: PTZ) Pethealth
More informationGreg Flower Wealth Management. Discretionary Wealth Management
Greg Flower Wealth Management Discretionary Wealth Management Disclaimer The information included in this document, including any opinion, is based on various sources believed to be reliable, but its accuracy
More informationBUY. Target: $0.90. Lifesciences - Biotechnology. Live and Let Dye. Investment highlights
Osprey Medical Inc OSP : ASX BUY Target: $0.90 AUS Update 1 Matthijs Smith +61 3 8688 9107 matthijs.smith@canaccord.com.au COMPANY STATISTICS: Share Price $0.45 Valuation $0.90 12 Month Range $0.31 - $0.69
More informationKabel Deutschland reports 7.3% revenue growth for the second quarter
INVESTOR RELATIONS RELEASE Kabel Deutschland reports 7.3% revenue growth for the second quarter Unterfoehring, November 9, 2015 Kabel Deutschland Holding AG ( Kabel Deutschland, KDH or the Company ), Germany
More informationInterim report as at 31 March 2014. Unit sales, revenue and profit increase Dividend increases to 2.90 per share Stock split ratio of two-for-one
Interim report as at 31 March 2014 Unit sales, revenue and profit increase Dividend increases to 2.90 per share Stock split ratio of two-for-one Fielmann Aktiengesellschaft Group interim report as at 31
More information